admin – Anabio R&D

LiveSpo Dia30 and LiveSpo Navax Multi-Strain Bacillus Spore Formulations for Digestive and Respiratory Health Presented at Pharmacity’s Annual Conference

At the Pharmacity Annual Conference held in Ho Chi Minh City on November 14, 2025, Assoc. Prof. Dr. Nguyen Thi Van Anh – representative of the ANABIO R&D Spobiotic Research Center and scientific advisor to LiveSpo Pharma – delivered a presentation titled “LiveSpo Dia30 and LiveSpo Navax: Multi-strain Bacillus spore formulations supporting the treatment of gastrointestinal and respiratory infections and reducing antibiotic dependence.”

During the presentation, Dr. Van Anh provided an overview of the technology platform and key advantages of the products, as well as clinical evidence from collaborative studies conducted with the Vietnam National Children’s Hospital and Hanoi Medical University. These included clinical trials of LiveSpo Dia30 in children with prolonged diarrhea; LiveSpo Navax in children with RSV–bacterial coinfection pneumonia; and the preventive effects of LiveSpo Navax against respiratory infections in preschool children. The data were shared with more than 500 pharmacists across the Pharmacity system, equipping them with deeper clinical insights into the products.

In addition to demonstrating clear benefits in shortening treatment duration by 1–2 days and reducing antibiotic use by 15–25%, the presentation emphasized the mechanisms of action of these formulations—restoring microbiome balance in both the gut and the nasal cavity, and modulating intestinal and nasal inflammation by reducing excessive pro-inflammatory cytokine secretion while enhancing anti-inflammatory cytokines.

Alongside presentations from major industry partners such as Opella, AstraZeneca, Bayer, GSK, and Meripharmex on topics related to the research, production, and commercialization of gastrointestinal, respiratory, gynecological therapeutics and health supplements, Dr. Van Anh’s report highlighted an innovative approach: the use of LiveSpo Bacillus spore probiotics to rapidly improve symptoms, shorten treatment time, and reduce the need for antibiotics. This contribution underscores an important advancement in supporting digestive and respiratory health, particularly for children.

ANABIO R&D’s Spobiotic Research Center Presents LiveSpo Navax at IDWeek 2025: International Scientific Exchange on Infectious Diseases

At IDWeek 2025, held in Atlanta, Georgia, USA, from October 19-22, 2025, Dr. Nguyen Hoa Anh representing LiveSpo Pharma and Assoc. Prof. Dr. Nguyen Thi Van Anh representing the Spobiotic Research Center – ANABIO R&D, presented new research findings on the effectiveness of nasal-spray Bacillus spores in preventing respiratory infections in children. This study is part of a collaborative effort among the Institute for Preventive Medicine and Public Health – Hanoi Medical University, Hanoi University of Public Health, and several other research institutions.

The conference brought together more than 10,000 physicians and scientists from over 100 countries and is recognized as one of the world’s leading forums in infectious diseases and antimicrobial resistance. IDWeek features a wide range of cutting-edge scientific updates through plenary sessions, keynote lectures, pre-meeting workshops, symposia, oral presentations, and poster sessions across specialized tracks such as antimicrobial resistance and stewardship, HIV, pediatric infectious diseases, public health, respiratory, gastrointestinal, urinary and sexually transmitted infections, epidemiology, and community healthcare.

The team’s poster booth attracted strong interest from many infectious disease physicians, hospital-based laboratory researchers, and R&D specialists from numerous countries, including the United States, the United Kingdom, Switzerland, France, Sweden, Spain, Colombia, Canada, Japan, Brazil, China, India, and Tanzania.

Throughout the exhibition, the team engaged in scientific discussions with visitors on topics related to LiveSpo Navax-the nasal-spray Bacillus spore probiotic for preventing and supporting the treatment of respiratory infections. Key discussion themes included product composition and mechanisms of action, modulation of the nasal microbiome, and its role in preventing and alleviating respiratory infections.

Many scientists expressed particular interest in the concept of a “nasal-spray probiotic,” viewing it as an innovative direction in microbial technology for respiratory health protection. They highly appreciated the product’s safety profile-showing no mucosal irritation and no adverse effects reported during clinical trials. Several researchers were especially intrigued by the adhesion and activity of Bacillus spores on the nasal mucosa, their potential to protect against multiple respiratory viruses, and the prospect of expanding research into other population groups beyond children.

Participating in IDWeek 2025 provided an important opportunity for ANABIO R&D’s Spobiotic Research Center to present Vietnam’s scientific achievements to the international community, while expanding collaborations in probiotics and in the biological, safe control of infectious diseases.

KỶ NIỆM 3 NĂM THÀNH LẬP TRUNG TÂM NGHIÊN CỨU BÀO TỬ LỢI KHUẨN(18/05/2022 – 18/05/2025)

Ngày 18/05/2025 đánh dấu cột mốc 3 năm hình thành và phát triển của Trung tâm Nghiên cứu Bào tử Lợi khuẩn (Spobiotic Research Center) – đơn vị tiên phong tại Việt Nam trong nghiên cứu và ứng dụng công nghệ bào tử lợi khuẩn vì sức khỏe cộng đồng. Với sứ mệnh “Vì tương lai không kháng sinh”, Trung tâm đã không ngừng đổi mới và nỗ lực phát triển các sản phẩm sinh học an toàn, hiệu quả phục vụ y tế dự phòng và hỗ trợ điều trị.

Những thành tựu nổi bật sau 3 năm hoạt động:

Nghiên cứu và thử nghiệm lâm sàng:
Trung tâm đã phối hợp triển khai nhiều đề tài nghiên cứu và thử nghiệm lâm sàng với các sản phẩm tiêu biểu như LiveSpo® NAVAX (4 đề tài), LiveSpo® PREG-MOM & KIDS (1 đề tài), LiveSpo® CLAUSY & DIA30 (1 đề tài), và LiveSpo® X-SECRET (2 đề tài). Các nghiên cứu đã cung cấp bằng chứng khoa học về độ an toàn và hiệu quả của bào tử lợi khuẩn Bacillus trong hỗ trợ điều trị các bệnh lý hô hấp, tiêu hóa và phụ khoa.
Công bố khoa học:
Đã có hơn 9 bài báo quốc tế, trong đó có 4 bài đăng trên tạp chí Nature Scientific Reports, cùng với 15 bài báo trong nước và 12 báo cáo hội nghị khoa học. Những công bố này góp phần khẳng định năng lực nghiên cứu và vị thế học thuật của Trung tâm trên trường khoa học quốc tế.
Sở hữu trí tuệ:
Trung tâm đã đăng ký thành công 5 sáng chế liên quan đến quy trình sản xuất các sản phẩm chủ lực như LiveSpo COLON, NAVAX, X-SECRET, cùng 2 sản phẩm thế hệ mới. Ngoài ra, đã bảo hộ thành công 8 nhãn hiệu độc quyền, thể hiện tính sáng tạo và định hướng phát triển bền vững trong các lĩnh vực tiêu hóa, hô hấp và phụ khoa.
Hợp tác trong nước và quốc tế:
Trung tâm mở rộng mạng lưới hợp tác với nhiều bệnh viện và đơn vị nghiên cứu như Bệnh viện Nhi Trung ương, Bệnh viện Phụ sản Hà Nội, ĐH Y Hà Nội, ĐH Y Dược Thái Bình, ĐH Kyoto, ĐH Tohoku, Viện Dinh Dưỡng, CDC Bắc Ninh… Từ đó từng bước khẳng định vai trò tiên phong của Việt Nam trong nghiên cứu bào tử lợi khuẩn.

Hơn cả những con số, chúng tôi tự hào vì mỗi công trình nghiên cứu, mỗi sản phẩm ra đời đều mang trong mình một sứ mệnh: “Vì tương lai không kháng sinh”

Trung tâm xin gửi lời tri ân sâu sắc tới toàn thể đội ngũ nghiên cứu viên, lãnh đạo, các phòng ban, đối tác và cộng sự đã đồng hành trong suốt chặng đường vừa qua.

LiveSpo® X-SECRET: A Breakthrough in Supporting the Treatment and Reduction of of Vaginitis Recurrence Using Vaginal-Spray Multi-strain High-Concentration Bacillus Spore Technology

Recently, the Probiotic Spore Research Center – ANABIO R&D Co., Ltd. collaborated with Hanoi Obstetrics and Gynecology Hospital to conduct the study “Evaluation of the Supportive Efficacy of Bacillus Probiotic Spores (LiveSpo^® X-SECRET) in the Treatment of Vaginitis.” The study, led by MSc. Dr. Nguyen Canh Chuong – Director of the Training and Direction Center, Hanoi Obstetrics and Gynecology Hospital, was highly evaluated and officially approved with an “Excellent” rating by the hospital’s review committee on April 26, 2025.
This collaboration marks an important milestone in the application of vaginal-spraying probiotics for supporting the treatment of gynecological diseases in general, offering a sustainable, safe solution while reducing the overuse of antibiotics and antifungal agents in vaginitis management.

***Principal Investigator presenting the study results at the project evaluation meeting***

This is the first study in the world to demonstrate the safety and outstanding efficacy of an intravaginal Bacillus spore probiotic spray in supporting the treatment and reduction of recurrent vaginitis symptoms in patients with bacterial vaginosis and sexually transmitted infections (STIs). After 28 days of LiveSpo^® X-SECRET use combined with standard treatment regimens, the data showed:

A 5.7-fold reduction in symptoms of inflammation, itching, abnormal vaginal odor, and abnormal vaginal discharge compared to baseline. Notably, the improvement in itching was 3-fold higher, and the improvement in multi-symptom reduction (≥3 symptoms) was 6-fold higher compared to the control group (standard treatment combined with physiological saline spray), contributing to effective symptom control and reduction of recurrence after completing the 7–10 day course of antibiotics/antifungals.
A 275-fold decrease in Gardnerella vaginalis load and a 2.1-fold increase in Lactobacillus relative abundance compared to the control group, supporting natural restoration of the vaginal microbiota following antibiotic/antifungal therapy.
A 43–60% reduction in pro-inflammatory cytokines (IL-1β and IL-8) and a 66% increase in vaginal IgA levels compared to the control group, strengthening the local immune barrier and reducing the risk of recurrence.

A key highlight of this study is that LiveSpo^® X-SECRET not only rapidly improved clinical symptoms but also helped reduce inflammatory markers and restore the vaginal microbiota, providing a robust foundation for natural and sustainable prevention of vaginitis recurrence. The study was highly evaluated by the review committee for its practical applicability and excellent safety profile. LiveSpo^®X-SECRET is potential as an effective supportive solution in gynecological care, contributing to a shift in the management of vaginitis and reducing dependence on antibiotics and antifungal medications

Welcoming the Former CEO of Biogaia, the World-Renowned Probiotics Company, to the Spobio Research Center

On the morning of February 10, 2025, the Spobio Research Center was honored to welcome Mrs. Isabelle Ducellier, the former CEO of Biogaia, for a visit and consultation regarding the potential development of probiotic products for the international market. This meeting provided a valuable opportunity to share ANABIO R&D’s research advancements and receive expert insights from a leading specialist in the field.

The 60-minute exchange left a profound impression on Mrs. Isabelle Ducellier, owing to the outstanding research conducted by the R&D laboratory. The collaborations with prestigious institutions, including the Central Pediatric Hospital, Thai Binh University of Medicine and Pharmacy, and the National Institute of Nutrition, have contributed to documenting the tangible benefits of probiotics in supporting the treatment of respiratory, digestive, and various other health conditions.

During the meeting, the research team presented their flagship probiotic products: PregMom, KID, Dia30, Colon, Clausy, Navax, and X-secret. These products have demonstrated exceptional efficacy in clinical trials and have been featured in renowned scientific journals such as Nature Scientific Reports and ASM. Notable findings include:

LiveSpo Navax effectively alleviates symptoms of ARTI caused by RSV while reducing viral load, offering a simple, cost-effective treatment approach for viral infections in general.

LiveSpo Colon significantly improves symptoms of chronic intestinal inflammation, including colitis, diarrhea, and constipation, while enhancing inflammatory markers and quality of life after 30 days of treatment. These improvements have been documented through comparative colonoscopy images from before and after product use.

LiveSpo Clausy regulates inflammation through the Th17 mechanism and has shown particularly promising results in reducing the duration of prolonged diarrhea in children aged 3-24 months. This contributes to reducing antibiotic use, protecting gut microbiota, and promoting healthier growth in children.

LiveSpo X-secret effectively alleviates symptoms of STDs, reduces pathogenic bacterial load, and improves the vaginal microbiota.

LiveSpo DIA30 has demonstrated remarkable effectiveness in treating prolonged diarrhea in children by reducing inflammation and improving gut microbiota without requiring antibiotics.

LiveSpo KIDS and LiveSpo PREG-MOM effectively alleviate constipation and malnutrition in children while strengthening immune systems and restoring gut microbiota.

Significantly, all ANABIO probiotic products have proven safe, with no reported side effects in clinical studies. This evidence demonstrates the effectiveness of probiotics in reducing antibiotic treatment duration, aligning with ANABIO R&D’s overarching goal: “For a future without antibiotics.”

In addition to the achievements, Mrs. Isabelle Ducellier was particularly impressed by the community-focused vision that ANABIO’s founder has instilled in every member of the research team. The unity, relentless creativity, and determination to overcome challenges in completing each study clearly reflect their shared goal: to benefit public health, with a particular focus on children’s health.

This meeting not only provided an opportunity for the Spobio Research Center to showcase its scientific accomplishments to an international expert but also served as a testament to ANABIO R&D’s commitment to LiveSpo Pharma’s vision: “For a future without antibiotics.”

Here are some pictures from the tour

1 2 3 4 Next page

Author Archives: admin